Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells.
about
Glycomic Approaches for the Discovery of Targets in Gastrointestinal CancerPathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addictionErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapiesThe Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cellsActivation of the N-terminally truncated form of the Stk receptor tyrosine kinase Sf-Stk by Friend virus-encoded gp55 is mediated by cysteine residues in the ecotropic domain of gp55 and the extracellular domain of Sf-Stk.Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy.Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinaseChk2*1100delC Acts in synergy with the Ron receptor tyrosine kinase to accelerate mammary tumorigenesis in mice.Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase.Isolation of Fully Human Antagonistic RON Antibodies Showing Efficient Block of Downstream Signaling and Cell Migration.The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells.RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.Novel function of transcription factor Nrf2 as an inhibitor of RON tyrosine kinase receptor-mediated cancer cell invasion.Differential expression of sphingosine-1-phosphate receptors in abdominal aortic aneurysms.Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancerThe RON receptor tyrosine kinase is a potential therapeutic target in Burkitt lymphoma.Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment.Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160Crosstalk between RON and androgen receptor signaling in the development of castration resistant prostate cancerHost genetic background impacts modulation of the TLR4 pathway by RON in tissue-associated macrophages.Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis.Differential expression of RON in small and non-small cell lung cancers.Recepteur d'origine nantais (RON), more than a kinase: Role in castrate-resistant prostate cancer.Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics.Expression of the receptor tyrosine kinase recepteur d'origine nantais and its association with tumor progression in hypopharyngeal cancer.Prognostic significance of phosphorylated RON in esophageal squamous cell carcinoma.Autoinhibition of the Ron receptor tyrosine kinase by the juxtamembrane domain.Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase.Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers.Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1alpha-mediated invasion of breast carcinoma cells.Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain.The Ron receptor tyrosine kinase is not required for adenoma formation in Apc(Min/+) miceRON Signaling Is a Key Mediator of Tumor Progression in Many Human Cancers.RON is overexpressed in bladder cancer and contributes to tumorigenic phenotypes in 5637 cells.
P2860
Q26750872-EC0D45B6-8AC1-4355-BBD5-9FD1DA270AADQ26864275-B31A8876-FF42-4F6A-B1DE-E3AD7F303CF9Q30474678-EF6F1416-0ABE-4061-8D42-FF4B15F81E5DQ33563635-C65A5000-A38C-4194-9DC0-5DE6565C7E9FQ33592512-104B91A8-EF8A-4356-8688-F16035046D88Q33648896-8D8BA59C-3042-4FAE-A7BB-17C212CB94AFQ33652455-127940FA-067B-4F15-887A-23003E101BBFQ33703886-9F750F73-929F-46C7-8F44-5491BDA1E6B1Q34037017-945F67FB-9F34-41D9-852C-64D6126D5AB6Q34405019-AE6001EE-FBA5-4FEA-A889-F56B77D94ABEQ34518350-7772E04F-D43C-4689-8778-8B92E7FEB955Q35124768-514281AA-1156-45A3-936B-B22C3B6AB85FQ35146597-E81A9B53-81F2-42F7-B2EF-C21934788DD4Q35213365-C0106B5F-8A4C-4294-B68A-311CA090B9F1Q35882116-B490A551-53BF-403F-B44C-9EDE90946C24Q36824455-2CC81998-7B93-4784-A2E8-657647CD38F3Q36887780-379B79DA-FAA0-43AA-9F5B-B66918B8B26CQ36958365-CD979EB7-71E8-4585-B4BF-2ACECE7850CEQ36975164-2DE0C252-2E70-474B-BCF4-114EE21991AAQ37046523-16B89B48-B5E0-4AC0-996A-BE8D2BF72F33Q37077043-B31848FC-BB16-4BDC-B067-9C645FC92149Q37707571-2E5244B6-89B5-4EFC-9BAF-8B4A167346CFQ38403475-1A6DAF7C-AF44-47F9-AAE5-E398846BAA29Q38543678-A849CFE4-3831-4BCF-9CB1-C40DC4058AD8Q38922319-1784BCB3-E5EB-48EA-A791-AFE27AE9808CQ39032726-01B04486-C776-4311-9BC1-BEF9CF5A1D29Q39298765-FA81215B-A91B-4944-BA2A-448BC58EB462Q39442425-B7F988EF-FBD8-4C2A-928D-2E3DE27B7009Q39628474-3345E06E-13F2-4488-9ED8-DC0590B86081Q39676024-10325522-58E6-42B1-BD67-E2ADC4408E85Q39747567-4B438695-CF2A-4713-9D2D-B2FEED1D04D5Q39869337-DD9D9622-13AB-4381-BC1D-1CCB79A4D67EQ41660598-A98B1286-5382-438E-AE70-9FC356F82D6AQ42738854-C987052A-E836-4107-BE67-C6712E4975AFQ53591553-63D69B7B-BAF7-45D8-8FE2-C1AD35460243Q54979788-55D4F455-E351-4BD4-9254-69937AB85003
P2860
Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Altered expression of the RON ...... types in thyroid cancer cells.
@en
Altered expression of the RON ...... types in thyroid cancer cells.
@nl
type
label
Altered expression of the RON ...... types in thyroid cancer cells.
@en
Altered expression of the RON ...... types in thyroid cancer cells.
@nl
prefLabel
Altered expression of the RON ...... types in thyroid cancer cells.
@en
Altered expression of the RON ...... types in thyroid cancer cells.
@nl
P2093
P356
P1476
Altered expression of the RON ...... types in thyroid cancer cells.
@en
P2093
P2860
P304
P356
10.1002/PATH.2245
P577
2007-12-01T00:00:00Z